Message from the President
Toshifumi Akizawa, Doctor of Medicine
O-Force company was founded on August 24, 2017, as a company consisting of two divisions: the Catalytide Institute and Minamikaze Pharmacy. The Catalytide Institute has discovered a variety of short synthetic peptides (named Catalytide) as promising treatments for neurodegenerative diseases caused by protein aggregation (Alzheimer's disease, Parkinson's disease). In addition, Catalytides are also promising therapeutic agents against amyotrophic lateral sclerosis, IgA nephropathy, and a novel coronavirus. We have obtained many patents related to these discoveries and published numerous scientific papers. We are conducting development research in collaboration with a Japanese pharmaceutical company and the Kochi University School of Medicine. Catalytide Institute is also looking for new colleagues to work with us.
We look forward to working with you.